David Moatazedi Biography and Net Worth

Director of Biomerica

Mr. David Moatazedi has served as the President and Chief Executive Officer, and as a member of the of Board of Directors of Evolus, Inc. (NASDAQ: EOLS), since May 2018. Evolus is a publicly traded life sciences company headquartered in Orange County, California, with a market capitalization of approximate $500 million. From March 2017 to June 2020, David also served as an independent board member of Obalon Therapeutics, a publicly traded life sciences company that was later merged into ReShape Lifesciences Inc. From 2016 to 2018, David served as Senior Vice President at Allergan Inc. (“Allergan”), and division head of the U.S. Medical Aesthetics division. Prior to Evolus, Mr. Moatazedi worked in various other leadership positions within Allergan since 2005, including Vice President, Sales and Marketing of the U.S. Facial Aesthetics and the U.S. Plastic Surgery Divisions. Before Allergan, Mr. Moatazedi was a district manager for Novartis Pharmaceuticals. Mr. Moatazedi holds, an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.

What is David Moatazedi's net worth?: The estimated net worth of David Moatazedi is at least $939.23 thousand as of September 2nd, 2026. Mr. Moatazedi owns 499,592 shares of Biomerica stock worth more than $939,233 as of October 8th. This net worth approximation does not reflect any other investments that Mr. Moatazedi may own. Learn More about David Moatazedi's net worth.
How do I contact David Moatazedi?: The corporate mailing address for Mr. Moatazedi and other Biomerica executives is 17571 Von Karman Avenue, Irvine CA, 92614. Biomerica can also be reached via phone at (949) 379-2875 and via email at [email protected]. Learn More on David Moatazedi's contact information.
Has David Moatazedi been buying or selling shares of Biomerica?: David Moatazedi has not been actively trading shares of Biomerica within the last three months. Most recently, on Wednesday, August 26th, David Moatazedi bought 10,000 shares of Biomerica stock. The stock was acquired at an average cost of $1.60 per share, with a total value of $16,000.00. Following the completion of the transaction, the director now directly owns 40,625 shares of the company's stock, valued at $65,000. Learn More on David Moatazedi's trading history.
Who are Biomerica's active insiders?: Biomerica's insider roster includes Allen Barbieri (Vice Chairman), and David Moatazedi (Director). Learn More on Biomerica's active insiders.
Are insiders buying or selling shares of Biomerica?: During the last twelve months, Biomerica insiders bought shares 4 times. They purchased a total of 92,500 shares worth more than $148,000.00. The most recent insider tranaction occured on August, 26th when Director David Moatazedi bought 10,000 shares worth more than $16,000.00. Insiders at Biomerica own 18.0% of the company. Learn More about insider trades at Biomerica.
Information on this page was last updated on 8/26/2026.

David Moatazedi Insider Trading History at Biomerica

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/26/2026	Buy	10,000	$1.60	$16,000.00	40,625

David Moatazedi Buying and Selling Activity at Biomerica

Biomerica Company Overview

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

Today's Range

Now: $1.87

$1.86

$1.91

50 Day Range

MA: $2.01

$1.49

$2.78

2 Week Range

Now: $1.87

$1.45

$3.21

Volume

6,221 shs

Average Volume

36,841 shs

Market Capitalization

$5.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.38